This research could be a game-changer for the Parkinson's community. The Donald and Barbara Zucker School of Medicine at Hofstra, in collaboration with the Yale New Haven Psychiatry Hospital, is conducting a research study to investigate if ketamine can be used as a rapid-acting antidepressant for those living with Parkinson's disease. With up to 40% of Parkinson's patients experiencing anxiety and nearly 50% suffering from depression, this research is hopeful that it could offer a safe and effective alternative for those struggling with the mental health issues associated with the condition. We are hopeful that the findings from this research could bring new hope to those living with Parkinson's disease.